Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Descriptive summary of ACR20 response rate at weeks 22 and 30 by dose received at week 14 (intention-to-treat population)

From: A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

  No dose escalation (3 mg/kg) at week 14 Dose escalation (5 mg/kg) at week 14
  PF-06438179/GP1111 (n = 240), n (%) Infliximab-EU (n = 244), n (%) Treatment difference, % PF-06438179/GP1111 (n = 60), n (%) Infliximab-EU (n = 68), n (%) Treatment difference, %
Week 22
ACR20 response
 Yes 180 (75.0) 185 (75.8) − 0.82 23 (38.3) 27 (39.7) − 1.37
 No 58 (24.2) 58 (23.8)   36 (60.0) 36 (52.9)  
 Missing 2 (0.8) 1 (0.4)   1 (1.7) 5 (7.4)  
Week 30
ACR20 response
 Yes 169 (70.4) 181 (74.2) − 3.76 27 (45.0) 27 (39.7) 5.29
 No 65 (27.1) 55 (22.5)   29 (48.3) 30 (44.1)  
 Missing 6 (2.5) 8 (3.3)   4 (6.7) 11 (16.2)  
  1. ACR20 American College of Rheumatology criteria for ≥ 20% clinical improvement, Infliximab-EU Infliximab sourced from the European Union